EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.
EU regulator rejects Alzheimer's drug lecanemabThe European Medicines Agency (EMA) rejected a license for an Alzheimer's treatment due to serious side effects outweighing benefits.
Europe sidelines Alzheimer's drug: lessons must be learntThe EMA's cautious approach may deny patients access to effective Alzheimer's treatment, contrasting with global acceptances of lecanemab.
A scientific rebellion to get Europe to approve a controversial Alzheimer's drugLecanemab represents a breakthrough for Alzheimer's treatment but faces significant controversy regarding its efficacy, safety, and accessibility.
Will the NHS ever pay for the new era of dementia drugs?The NHS has denied funding for lecanemab, the first drug shown to slow Alzheimer's progression, due to cost-effectiveness concerns.
Debate rages over Alzheimer's drug lecanemab as UK limits approvalThe debate over lecanemab centers on balancing its potential cognitive benefits against the risks and costs involved.
First drug to slow Alzheimer's too costly for NHSNICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs.
Will the NHS ever pay for the new era of dementia drugs?The NHS has denied funding for lecanemab, the first drug shown to slow Alzheimer's progression, due to cost-effectiveness concerns.
Debate rages over Alzheimer's drug lecanemab as UK limits approvalThe debate over lecanemab centers on balancing its potential cognitive benefits against the risks and costs involved.
First drug to slow Alzheimer's too costly for NHSNICE has decided against funding lecanemab on the NHS, citing insufficient benefits relative to the treatment costs.
A Drug to Slow Alzheimer's Is Finally Available. How Are Patients Faring?The Alzheimer's drug lecanemab offers hope with modest benefits and high risks, as strict criteria determine patient eligibility.